KR20200069621A - Composition for enhancing exercise capacity comprising mealworm protein - Google Patents

Abstract

The present invention relates to a composition for treating or alleviating muscle diseases, or enhancing exercise performance ability containing mealworm protein as an active component. The composition improves endurance and muscle strength of a mouse model, and increases the expression of factors related to exercise performance ability, thereby being able to be usefully used as the composition for treating or alleviating muscle diseases, or enhancing exercise performance ability.

Description

Composition for enhancing exercise capacity comprising mealworm protein

The present invention relates to a pharmaceutical, health functional food and health food composition for the treatment, improvement or improvement of exercise performance of muscle disease comprising wheat worm protein as an active ingredient.

Muscular strength refers to the maximum strength that a muscle or muscle tissue can exert, and exercise ability refers to the ability to rapidly, strongly, long, and skillfully perform physical movements performed in daily life or sports using these muscle strengths. When muscles are lost due to congenital disabilities or acquired reasons such as lying in the hospital for a long time, muscle power decreases and the ability to exercise decreases, so it is required to enhance exercise performance. It is required to enhance athletic performance.

As a method for enhancing exercise performance, scientific training, diet, technical equipment improvement, and exercise ability improvement aids according to exercise events are used. Among the above methods, research related to functional supplements for improving athletic performance has been actively conducted regardless of the East and West. However, most exercise supplements used in the West are caffeine and anabolic steroids, and most of them have side effects and there is a risk of doping. Accordingly, in recent years, studies to develop functional supplements using natural products with guaranteed safety have been actively conducted, but since they are still incomplete, it is necessary to study supplements without side effects while effectively enhancing exercise performance.

On the other hand, the brown beetle ( Tenebrio molitor ) is an insect that is dark brown and about 15 mm long, and the adult usually lays eggs in grains. The eggs hatch after 1-2 weeks, and the hatched larvae are called worm Call it. The brown larva larva (wheatworm) becomes a pupa through 9-20 molts and fables as an adult, nocturnal and distributed worldwide. Wheat worms have been studied to have therapeutic or preventive effects on cancer, alcoholic liver toxicity, and dementia. However, the ability of wheat worms to exercise and improve muscle strength is not yet known.

Korean Patent Publication No. 10-2015-0050712

The present inventors completed the present invention by confirming the exercise performance ability and muscle strength enhancing activity of wheat worm protein.

It is an object of the present invention to provide a pharmaceutical, health functional food and health food composition for treating, improving or improving exercise performance, including muscle worm protein as an active ingredient.

In order to achieve the above object,

The present invention provides a pharmaceutical composition for treating muscle disease or improving exercise performance, which includes wheat worm protein as an active ingredient.

In addition, the present invention provides a health functional food and a health food composition for improving muscle disease or improving exercise performance, including wheat worm protein as an active ingredient.

Since the composition for treating, improving or improving the performance of muscle disease containing the wheat worm protein of the present invention as an active ingredient, it was confirmed that the endurance and muscle strength of the mouse model were increased and the expression of factors related to the performance of exercise was increased, and thus muscle disease. It can be usefully used as a composition for treatment, improvement, or improvement in athletic performance.

1 is a result of measuring the swimming ability after ingesting wheat worm protein, whey protein, and soy protein after exercise for 4 weeks climbing exercise for C57BL6 mice.
Figure 2 shows the results of measuring grip strength after ingesting wheat worm protein, whey protein, and soy protein after exercising C57BL6 mice for 4 weeks.
FIG. 3 shows the results of measuring the mRNA expression of Cytochrome C in the calf muscle after ingesting wheat worm protein, whey protein, and soy protein after exercise for 4 weeks in climbing exercise for C57BL6 mice.
FIG. 4 shows the results of measuring the mRNA expression of PPARγ in calf muscle after C57BL6 mice are exercised for 4 weeks and after ingesting wheat worm protein, whey protein, and soy protein.
Figure 5 shows the results of measuring the mRNA expression of Caspase-3 in the calf muscle after ingesting wheat worm protein, whey protein, and soy protein after exercise for 4 weeks in climbing exercise for C57BL6 mice.

Hereinafter, the present invention will be described in detail.

Pharmaceutical composition for treating muscle disease or improving exercise performance

The present invention relates to a pharmaceutical composition for treating muscle disease or improving exercise performance, comprising wheat worm protein as an active ingredient.

In the pharmaceutical composition according to the present invention, the wheat worm protein may be prepared by hydrolyzing the oil milked from the wheat worm with a protease, followed by concentration and lyophilization, and the protease may be preferably a nutrase. However, it is not limited thereto.

In the present specification, the muscle disease is a muscle disease caused by deterioration of muscle function, muscle wasting or muscle degeneration, and is preferably a disease reported in the art. The muscle wasting or degeneration is caused by genetic factors, acquired factors, aging, and the like, and muscle wasting is characterized by gradual loss of muscle mass, muscle weakness, especially weakening and degeneration of skeletal or veterinary muscle and cardiac muscle. Examples of related diseases include atony, muscle atrophy, muscle dystrophy, muscle degeneration, myasthenia gravis, cachexia, and sarcopenia. The composition of the present invention has an effect of increasing muscle mass, and the muscle does not limit its type.

In this specification,'muscular' refers to the tendon, muscle, tendon, and'muscular function' or'muscle function' refers to the ability to exert power by contraction of muscles, and muscles overcome resistance. Muscle strength capable of exerting maximal contractility; Muscle endurance, the ability of a muscle to indicate how long or how many times it can contract and relax at a given weight; And instantaneous power, which is the ability to exert strong power in a short time. The muscle function is proportional to the muscle mass, and the term'muscle function improvement' means to improve muscle function in a more positive direction.

In the present specification,'exercise ability' is when the physical motion seen in everyday life or sports is externally divided into running, running, throwing, swimming, etc., the motion is fast, strong, accurately, long, skillful It indicates the degree to be able to do, and the ability to perform exercise is defined as factors such as muscle strength, agility and endurance. In the present invention, the term'improving athletic performance' refers to improving or improving athletic performance, and may preferably mean improving muscle strength or endurance.

When the composition of the present invention is a pharmaceutical composition for improving athletic performance, it can be used for prevention or treatment of diseases caused by deterioration of athletic performance. Examples of diseases related to this include degenerative diseases, mitochondrial abnormalities, endurance, dyslexia, muscular dysfunction, lethargy, muscle atrophy, and depression. The composition of the present invention has an effect of improving exercise performance, and does not limit the form and type of exercise.

In one embodiment of the present invention, the wheat worm protein according to the present invention (Example 1) increases the exercise performance (see FIGS. 1 and 2 ), while reducing the expression of Cytochrome C, PPARγ and Caspase 3 (FIGS. 3 to 3 ). 5) It was confirmed that it can reduce muscle fatigue, reduce body fat, and reduce muscle loss.

The pharmaceutical composition according to the present invention may be administered in various dosage forms, oral and parenteral, during clinical administration, preferably oral administration, transdermal administration, topical administration, inhalation administration, intranasal administration, intravenous administration, intradermal administration It may be administered in any one or more formulations selected from the group consisting of administration, intraperitoneal administration, injection and subcutaneous injection formulations. When formulated, it is usually prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.

Solid preparations for oral administration include tablets, patients, powders, granules, capsules, troches, etc. These solid preparations include at least one excipient such as starch, calcium carbonate, or one or more excipients of the wheatworm protein of the present invention. It is prepared by mixing sucrose, lactose, or gelatin. In addition, lubricants such as magnesium stearate talc are used in addition to simple excipients. Liquid preparations for oral administration include suspending agents, intravenous solutions, emulsions or syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. are included. Can be.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, lyophilized preparations, suppositories, creams, gels, sprays, drops, and the like. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, etc. may be used.

The effective dosage for the human body of the pharmaceutical composition of the present invention may vary depending on the patient's age, weight, sex, dosage form, health status and disease level, and is generally about 0.01-1000 mg/kg/day, preferably It may be 0.1-500 mg/kg/day, and may be dividedly administered once to several times a day at regular time intervals according to the judgment of a doctor or pharmacist.

The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers.

The pharmaceutical composition of the present invention may also provide a formulation of an external preparation containing wheat worm protein as an active ingredient.

When the pharmaceutical composition of the present invention is used as an external preparation for skin, fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, interfaces Skin such as activators, water, ionic emulsifiers, nonionic emulsifiers, fillers, metal ion blockers, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic activators, lipophilic activators or lipid vesicles It may contain adjuvants commonly used in the field of dermatology such as any other ingredients commonly used in external preparations. In addition, the ingredients may be introduced in an amount commonly used in the field of dermatology. When the pharmaceutical composition of the present invention is provided as an external preparation for skin, it is not limited thereto, and may be a formulation such as ointment, patch, gel, cream or spray.

Health functional food and health food composition for improving muscle disease or improving exercise performance

In addition, the present invention relates to a health functional food composition for improving muscle disease or improving exercise performance, which includes wheat worm protein as an active ingredient.

The term "health functional food" used in the present invention refers to food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills, etc. using ingredients or ingredients having useful functionality for the human body. Here, the term'functional' refers to obtaining a useful effect for health use, such as regulating nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be manufactured by a method conventionally used in the general technical field, and may be prepared by adding raw materials and components conventionally added in the general technical field. In addition, the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a health functional food. The health functional food composition of the present invention can be manufactured in various types of dosage forms, and has the advantage of not having side effects that may occur when taking the drug for a long time using food as a raw material, unlike general drugs, and has excellent portability. The health functional food of the present invention can be consumed as an adjuvant to enhance the effect of a product for improving muscle disease or improving exercise performance.

In addition, the present invention relates to a health food composition for improving muscle disease or improving athletic performance, including wheat worm protein as an active ingredient.

When the composition of the present invention is used as a health functional food composition or a health food composition, the wheat worm protein may be added as it is or used with other foods or food ingredients, and may be suitably used according to a conventional method. The composition may include a food additive that is food-acceptable in addition to the active ingredient, and the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment). In general, the amount of the composition in the health food and health functional food can be added in 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake for the purpose of maintaining health or for the purpose of controlling health, the amount may be below the above range, and since there is no problem in terms of safety, the wheat worm oil according to the present invention may be used in an amount above the above range. Can be.

The term "food supplement additive" used in the present invention means a component that can be supplementally added to food, and is added to prepare a health functional food or health food of each formulation, and can be appropriately selected and used by those skilled in the art. Examples of food supplements include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like, but the types of food supplements of the present invention are not limited by the examples.

In addition, there is no restriction on the type of health functional food or health food to which the composition of the present invention can be used. In addition, the composition comprising the wheat worm protein of the present invention as an active ingredient may be prepared by mixing a known additive with other appropriate auxiliary ingredients that may be contained in a health functional food according to the choice of those skilled in the art.

Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, dairy products including gums, ice cream, various soups, beverages, teas, drinks, alcoholic beverages, and There are vitamin complexes and the like, and the composition according to the present invention can be prepared by adding juice, tea, jelly, and juice prepared as the main component.

Since the wheat worm protein according to the present invention is a natural product as a raw material, even when used as a pharmaceutical or food composition, side effects may be less than that of a general synthetic compound, so it is safely contained in a pharmaceutical composition, a health functional food, and a health food composition to be usefully used. Can be.

Hereinafter, the present invention will be described in more detail by examples. It will be apparent to those skilled in the art that these examples are merely for more specifically describing the present invention, and the scope of the present invention is not limited to these examples.

<Example 1> Preparation of wheat worm protein

Wheat worm oil was obtained by milk expression of commercially available dried wheat worms, and water and neutrases 0.3% (w/w) in an amount corresponding to 15 times the total weight of the wheat worm oil. Was added and stirred at 65° C. for 2 hours. Then, the temperature was raised to 105°C and maintained for 20 minutes while inactivating the enzyme, and then filtered using a 100 mesh housing filter. The filtrate containing the wheat worm protein was collected and concentrated under reduced pressure at 70° C. to be 45° Brix or higher to prepare a wheat worm protein concentrate. The wheatworm protein concentrate was spray dried to obtain a final wheatworm protein (Example 1) in powder form. At this time, the content of the protein component contained in the obtained wheat worm protein (Example 1) was 64.55% or more, and the wheat worm protein of Example 1 was used in the following animal experiments.

< Preparation example > Experimental animal Preparations

The experimental animals were pre-adapted for 1 week after receiving 5 weeks old C67BL6 male mice from Nara Biotech (South Korea), and 8 animals were classified as follows. Control group (con), wheat worm protein 300mg/kg intake group (wheat worm), exercise group (EX), exercise group + low concentration of wheat worm protein (300mg/kg) group (EX+ wheat worm_L) and exercise + high concentration of wheat worm protein (600mg) /kg) intake group (EX + wheat worm_H), as a positive control exercise + whey protein 300mg / kg intake group (EX + whey) and exercise + soy protein 300mg / kg intake group (EX + soybean) was set to 7 groups. In the exercise experiment, an iron ladder with an inclination of 85°, a height of 135 cm, and an interval of 1.5 cm was installed, and the weight climbing was applied to the weight of the mouse corresponding to the tail of the mouse (climbing exercise) 10-12 times a day, Four weeks were performed for three days a week, and each climb took a break for 30 seconds. It was carried out step by step using a tower climbing exercise device to load 100% of the maximum weight. Protein was administered orally using zones after exercise.

<Experimental Example 1> Swimming exercise ability evaluation

In order to evaluate endurance 1 hour before dissecting the experimental animal, the experimental group (EX+milworm_L, EX+milworm_H) and the positive control group ingested the wheat worm protein, whey protein, and soy protein after the climbing exercise as in the above preparation example (EX+Whey and EX+Soybean) Exhausted swimming for the exercise group without protein (EX) and the control group (con) without climbing exercise and wheat worm protein 300mg/kg intake group (milworm) after climbing exercise Exercise was conducted.

Specifically, a plastic water tank (15 cm in diameter x 22 cm in height) was filled with water at 25°C and allowed to swim in the water tank. Swiming time (min) until the mice were further exhausted was measured, and when the nose of the mice sank below the water surface and failed to rise to the surface for more than 5 seconds, it was determined as exhaustion.

As a result, as shown in FIG. 1, the exercise group (EX) did not affect the swimming time compared to the control group (con), but the experimental group (EX+milworm_L, EX+milworm_H) had a swimming time compared to the control group (con). I could confirm the increase. It had a longer swimming time than the exercise + whey protein intake group (EX+ whey) and exercise + soy protein intake group (EX + soybean), which were positive controls, but there was no statistically significant difference.

Thus, it was confirmed that the wheat worm protein of Example 1 according to the present invention was excellent in improving endurance.

<Experiment 2> muscle strength evaluation

One day before dissecting the experimental animals, a grip strength test was performed to measure the muscle strength of the mice. The maximum force presented when the mouse's forearm can no longer hold the device's bar by holding the mouse's tail and holding the device's bar with two forefoot is considered grip strength (g) Did. It was measured once a week and the highest was used by measuring 5 times for each mouse.

As a result, as shown in FIG. 2, the experimental group (EX+milworm_L, EX+milworm_H) showed that both concentrations significantly improved muscle strength when compared with the control (con). In particular, the exercise + wheat worm protein high-concentration intake group (EX+ wheat worm_H) was statistically significantly improved compared to the exercise (EX) group with the exercise + whey protein intake group (EX + whey).

Thus, it was confirmed that the wheat worm protein of Example 1 according to the present invention was excellent in improving muscle strength.

<Experiment 3> Evaluation of biomarker expression related to athletic performance improvement

Among biomarkers related to athletic performance improvement, the protein expression levels of Cytochrome C, PPAR-r and caspase 3 were measured using a Western blot method.

Specifically, after 4 weeks of exercise and the period of ingestion of the test substance and the exhausted swimming exercise was completed, 1 hour after the mice were sacrificed, the gastrocnemius muscle was extracted and stored in E-tube and stored in liquid nitrogen. After that, the tissue was crushed using a homoganizer, and then RNA was extracted using a TRIzol reagent. The extracted RNA was quantified using nanodrops. Quantitative RNA was synthesized with cDNA under conditions of 45°C for 60 minutes and 70°C for 15 minutes using bioneer cDNA synthesis kit and PCR machine. Synthesized cDNA, SYBR reagent, and specific primers were measured using real time-PCR machine to measure mRNA expression levels of Cytochrome C, PPARγ, and caspase 3 among biomarkers related to exercise performance improvement.

Cytochrome C mRNA expression is increased by the permeability of the inner and outer membranes when the electrons generated in the mitochondrial oxidation process are not smoothly transmitted to the mitochondrial respiration during exercise, resulting in apoptosis, which is increased by the movement of the cytochrome C into the cytoplasm. PPARγ is a transcription regulator essential for the formation and differentiation of adipocytes in the body, and is known to play a variety of physiological roles in adipose, liver, and muscle tissues as well as adipocyte differentiation. Particularly, as a representative protein whose activity increases during fat differentiation, it is closely related to diabetes and fat, and thus, after exercise, a decrease in PPARγ expression shows a decrease in body fat, that is, an obesity inhibitory effect. Caspase 3 is also an important biomarker for apoptosis. Increased mRNA expression of Caspase 3 after exercise indicates that the loss of muscle cells increased.

As shown in FIGS. 3 to 5, mRNA expression levels of Cytochrome C, PPARγ and Caspase 3 were significantly decreased in the experimental group (EX+milworm_L, EX+milworm_H) compared to the control (con). I could confirm.

Therefore, the wheat worm protein of the present invention (Example 1) increases the ability to exercise (Figs. 1 and 2), while reducing the expression of Cytochrome C, PPARγ and Caspase 3 (Figs. 3 to 5), reducing muscle fatigue It was confirmed that it can reduce body fat and reduce muscle loss.

So far, the present invention has been focused on the preferred embodiments. Those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered in terms of explanation, not limitation. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent range should be interpreted as being included in the present invention.

Claims (7)

A pharmaceutical composition for treating muscle disease or improving exercise performance, comprising a mealworm protein as an active ingredient.
According to claim 1,
The wheat worm protein is a pharmaceutical composition characterized in that the oil milk from the worm is prepared by hydrolyzing with proteolytic enzymes and then concentrated and lyophilized.
According to claim 1,
The muscle disease is characterized in that the muscle disease due to muscle function degradation, muscle wasting or muscle degeneration, muscle disease treatment or pharmaceutical composition for improving exercise performance.
According to claim 3,
The muscle disease is characterized by at least one selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, and sarcopenia. Pharmaceutical composition for the treatment of disease or improvement of exercise performance.
According to claim 1,
The improvement in athletic performance is characterized by preventing or treating one or more diseases selected from the group consisting of degenerative diseases, mitochondrial disorders, endurance, hypokinesia, lethargy, muscular dysfunction, muscle disposal and depression, etc. A pharmaceutical composition for improving treatment or exercise performance.
A health functional food composition containing wheat worm protein as an active ingredient, for improving muscle disease or improving exercise performance.
A health food composition containing wheat worm protein as an active ingredient, for improving muscle disease or improving exercise performance.

Images